explore -WSS

explore

author：fashion 2025-09-27 22:50:05 - browse：521

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Listen: Who gets the credit for GLP

WSS

Mindstrong's demise and the future of mental health care

Hospitals consider fixing cancer drug shortages on their own

How medical schools plan to diversify without affirmative action

White House touts steps to stem shortages of cancer treatments

WHO recommends dropping component of many flu vaccines

Health tech startups drop sharply from 2021 highs

knowledge

explore

focus

United colonoscopy coverage change 'may cost lives,' doctors say

WATCH: Why do bright lights make us see spots?

The high cost of giving birth even with insurance

Health tech startups drop sharply from 2021 highs

How one medical school became remarkably diverse

FDA approves updated Covid vaccines

Duchenne breakthrough therapy leaves behind pioneering families

WHO recommends dropping component of many flu vaccines

In age of alternative facts, a scholarly course on calling out crap

Regeneron agrees to White House price limits on anti

focus

Walmart eyes Medicare Advantage provider ChenMed

New Covid vaccine is recommended for everyone 6 months or older

FDA proposes changes to key medical devices approval pathway

Menendez indictment could see pharma lose a key ally

Shingles, which affected Dianne Feinstein, is on the rise

Pig kidney works a record two months in donated body

explore

hotspot

explore

explore